西蒙顾和：2024年生物制药第一种药物在欧洲成功上市和商业化的七个秘密成分白皮书（英文版）

Transitioning from an R&D-focused biopharma company to a commercially viable operation is already a challenging endeavor, and the prospect of having to master complex European launch requirements while also steering US business makes this shift even more daunting. To help companies assess the general viability of such ventures, this Simon-Kucher whitepaper identifies common characteristics among independent operations and carves out key managerial implications to enable business lead